Variants in the triggering receptor expressed on myeloid cells 2 (TREM2) gene have been demonstrated to increase the risk of late-onset Alzheimer’s disease (AD) and Nasu-Hakola disease. The gene discussed is TREM2; the disease is early-onset autosomal dominant Alzheimer disease.